Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Saved in:
| Title: | Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. |
|---|---|
| Authors: | Pi-Sunyer FX; Obesity Research Center, St Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA. fxp1@columbia.edu, Aronne LJ, Heshmati HM, Devin J, Rosenstock J |
| Corporate Authors: | RIO-North America Study Group |
| Source: | JAMA [JAMA] 2006 Feb 15; Vol. 295 (7), pp. 761-75. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
